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Increasing evidence has placed eukaryotic translation initiation factor 4E (eIF4E) at the hub of
tumor development and progression. Several studies have reported that eIF4E is over-expressed
in cervical cancer; however, the mechanism remains elusive. The results of this study further con-
ﬁrm over-expression of eIF4E in cervical cancer tumors and cell lines, and we have discovered that
the transcription of eIF4E is induced by protein E6 of the human papillomavirus (HPV). Moreover,
regulation of eIF4E by E6 signiﬁcantly inﬂuences cell proliferation, the cell cycle, migration, and
apoptosis. Therefore, eIF4E emerges as a key player in tumor development and progression and a
potential target for CC treatment and prevention.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
A growing body of evidence indicates that translational regula-
tion plays a critical role in the control of cell proliferation and
growth. Eukaryotic translation initiation factor 4E (eIF4E) is a key
player in translational control. As a rate-limiting molecule, eIF4E
is critical in the process of cap-dependent translation initiation.
Thus, it has been considered one of the main switches controlling
eukaryotic translation [1]. The human eIF4E gene is located on
chromosome 4q21–q25 and encodes a 24-kD polypeptide. EIF4E
also appears to be a cap binding protein (CBP); it speciﬁcally recog-
nizes the cap structure of mRNA and regulates mRNA translation in
many key steps, such as bringing mRNA to the 43S initiation com-
plex and unraveling the secondary structure of 50 untranslated re-
gions (50-UTRs). The eIF4E molecule selectively transports speciﬁc
mRNAs of vascular endothelial growth factor (VEGF), cyclin D1,and ornithine decarboxylase (ODC) from nucleus to cytoplasm for
translation.
This recently discovered oncogene, EIF4E, has been found to
contribute to tumor occurrence and development. It is over-ex-
pressed in squamous cell carcinoma of the head and neck, breast
cancer, bile duct cancer, and other tumors [2,3]. eIF4E is also asso-
ciated with tumor occurrence, invasion, and metastasis [2,3]. Over-
expressed eIF4E can unlock the long and highly structured 50-UTRs
of weak mRNA in tumor cells. This ability results in the enhanced
expression of weak mRNA from the genes of c-myc, p53, cyclinD1,
TGF-b, VEGF, and MMP9 [4]. These targeted molecules then partic-
ipate in cancer development and metastasis by promoting cell pro-
liferation, transformation, and angiogenesis. Although eIF4E
control of the translation of many oncogenes and growth factors
has been well studied, the upstream regulation of eIF4E itself re-
mains poorly studied, especially in some speciﬁc tumors such as
human papilllomavirus (HPV)-related cervical cancer (CC).
Few studies have been conducted on the relationship between
eIF4E and CC. Van Tranppen et al. [5] analyzed eIF4E over-expres-
sion in CC tissues using RT-PCR and speculated that eIF4E has a
large part in the development of CC. Lee et al. [6] further
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expression is signiﬁcantly enhanced following the progression of
cervical malignant lesions. However, little attention has been fo-
cused on the mechanism of eIF4E over-expression in CC.
Cervical cancer has the second highest incidence among malig-
nant tumors in females. Because HPV DNA is detected in almost all
CC tissues [7,8], it has been generally accepted that HPV infection is
an essential factor causing CC and precancerous lesions.
HPV E6 is one of the most important carcinogenic molecules en-
coded by high-risk HPV DNA. E6 protein is composed of 151 amino
acid residues, contains two zinc-ﬁnger structures, each including
two C-X-X-C sequences, and plays a crucial role in the occurrence
and development of CC through direct and/or indirect molecular
interactions. For example, E6 suppresses the activity of p53 and
the PDZ family of signaling proteins and promotes the activity of tel-
omerase [9]. We hypothesize that eIF4E over-expression in CC is
caused by the HPV virus oncogene E6. Until now, no research on this
issue has been published. In this study, we aimed to conﬁrm that E6
regulates eIF4E transcription and, in turn, the cell biology of CC. Our
results help elucidate the mechanisms of eIF4E over-expression in
CC and add to the knowledge base concerning E6 carcinogenesis in
CC, which will provide new targets for CC diagnosis and treatment.2. Materials and methods
2.1. Clinical specimens
During 2009–2011, a total of 98 specimens were collected from
the Pathology Department of the Afﬁliated Hospital of Guangdong
Medical College, Guangdong Province, China. Diagnoses were con-
ﬁrmed by at least two pathologists. Among these specimens, 21
were from cases of chronic cervicitis, 25 were from cases of cervical
intraepithelial neoplasia stage I (CIN I), 31 were from cases of CIN
stage II or III (CIN II–III), and 21 were from cases of cervical squa-
mous cell carcinoma (SCC).
2.2. Cell lines and transfection
Two CC cell lines, HPV-positive Hela and HPV-negative C33A
were used in this study. The cells were grown in standard culture
medium (RPMI 1640 containing 10% FBS, 2 mmol/L L-glutamine,
50 U penicillin and 50 lg/ml streptomycin) at 37 C under a 5%
CO2 atmosphere.
The liposome method was employed for the gene transfection.
In the experiment, cells were divided into three groups: the un-
treated (mock) group, the negative control (NC) group, and the
treated group. A volume of 25 ll Lipofectamine™ 2000 (Invitrogen,
Guangzhou, China) reagent was used per migrogram of DNA.
2.3. eIF4E immunohistochemistry and immunocytochemistry
Immunohistochemical labeling of 4-lm-thick, formalin-ﬁxed,
parafﬁn-embedded sections of cervical tissue was achieved using
mAbs speciﬁc for eIF4E (1:25, Santa Cruz, California, USA). IHC
was performed as previously described [10]. The sections were
pre-treated using the heat-mediated antigen retrieval method with
sodium citrate buffer for 20 min. Detection was performed using a
horseradish peroxidase (HRP)-conjugated compact polymer sys-
tem (Zhongshanjinqiao Biological Technology Ltd. Co., Beijing, Chi-
na). The sections were ﬁnally counterstained with haematoxylin.
For the negative control, phosphate-buffered saline (PBS) was used
instead of the ﬁrst antibody. Sections labeled with eIF4E antibody
were incubated at 4 C overnight. A DAB chromogenic reagent kit
(Zhongshanjinqiao Biological Technology) was used for visualiza-
tion. A spacer-protein (SP) labeling method [11,12] was used forIHC. In the experiment, a positive control and a PBS negative con-
trol were applied to each group.
2.4. Plasmids and small interference RNAs
shE6 interference plasmids were constructed by Genechem
Compan, Shanghai. Three pairs of shE6 (HPV16) sequences were
shE6-1 (stem: CCTACAAGCTACCTGATCT, loop: AGTGAAGCCACA-
GATGTA, stem: AGATCAGGTAGCTTGTAGG); shE6-2 (stem: GGAAC
TTACAGAGGTATTT, loop: AGTGAAGCCACAGATGTA, stem: AAA-
TACCTCTGTAAGTTCC); and shE6-3 (stem: GCAGAGAAACACAAG-
TATA, loop: AGTGAAGCCACAGATGTA, stem: TATACTTGTGTTTCTC
TGC). E6 and E6 mutant expression plasmids were constructed
using the pEGFP-C5 vector as described previously [13]. E6 con-
tained the wild-type E6 of HPV16. The E6 mutant contained a point
mutation (G to T) at nt 138 as well as a deletion mutation of 15 nts
from nt 348 to nt 363 of E6.
Small interference RNA of eIF4E (sieIF4E) was synthesized
by GenePharma Co., Ltd. (Shanghai, China). The sieIF4E was
received as desalted, deprotected oligonucleotides. The sequences
of sieIF4E were 50-GGAUAUUAUAAAUAGAUUATT-30, reverse 50-
UAAUCUAUUUAUAAUAUCCTT-30. Normal control (NC) sequences
were 50-UUCUCCGAACGUGUCACGUTT-30, reverse 50-ACGUGACA-
CGUUCGGAGAATT-30.
2.5. Detection of E6 and eIF4E mRNA by RT-PCR and real-time PCR
The primer sequences were 5-CGAACCGTTGAATCCAGCAGAA-
30, reverse 50-CGAACCGTTGAATCCAGCAGAA-30 for E6; 50-
CTGCGGCTGATCTCCAAG-30, 50-CTGCGGCTGATCTCCAAG-30 for
eIF4E; 50-GAAGGTCGGAGTCAACGGATTT-30, 50-CCTGGAAGATGG
TGATGGGATT-30 for GAPDH (as the internal control).
RT-PCR was performed using the Access RT-PCR Kit (Promega
Corporation, WI, USA) according to the manufacturer’s protocols
on the GeneAmp PCR System 9700 (Applied Biosystems, Foster
City, CA, USA). For eIF4E ampliﬁcation, 0.05 lg total RNA was used
in 20 ll RT-PCR, and the reaction was carried out at 48 C for
45 min (RT), 95 C for 2 min (initial denaturation), 30 cycles of
denaturation at 95 C for 30 s, annealing at 54 C for 30 s, with an
extension at 72 C for 7 min.
Real-time PCR for ampliﬁcation and detection of DNA was per-
formed on the 7500 Real-Time PCR ABI system (Applied Biosys-
tems), using a 96-well plate format. PCR was carried out in
triplicate in a 25-lL reaction volume containing 12.5 ll Platinum
SYBRGreen qPCR SuperMix-UDG (Invitrogen, Guangzhou, China),
0.5 ll forward primer (10 lM), and 0.5 ll reverse primer (10 lM).
The reaction conditions for ampliﬁcation of DNA were 95 C for
2 min, followed by 40 cycles of 95 C for 15 s and 60 C for 1 min.
Data were analyzed using the sequence detection software version
1.6.3 acquired from Applied Biosystems.
2.6. CCK-8 cell proliferation assay
Cell proliferation was determined using a Cell Counting Kit-8
(CCK-8) according to the manufacturer’s protocol (Beyotime Insti-
tute of Biotechnology, Shanghai, China). CCK-8 allows convenient
assays using reagent WST-8. WST-8 is bio-reduced by cellular
dehydrogenases to an orange formazan product that is soluble in
medium. The amount of formazan produced is directly propor-
tional to the number of living cells. The detection sensitivity of
CCK-8 is higher than any other tetrazolium salts, such as MTT,
XTT, or MTS. Here, Hela or C33A cell suspension was inoculated
in a 96-well plate (104 cells/well). After culture, the plate was
pre-incubated in a humidiﬁed incubator (at 37 C, 5% CO2). A vol-
ume of 10 ll CCK-8 solution was added to each well of the plate,
and the incubation was continued for an additional 2 h. The
692 S. Wang et al. / FEBS Letters 587 (2013) 690–697experiment was performed in (at least) triplicate wells. The absor-
bance of the wells was measured using a micro-plate reader. Cell
proliferation ability was represented by the mean absorbance va-
lue (AV). Using the mean absorbance value, the proliferation rate
and inhibition rate were calculated as follows: proliferation rate
(%) = AVtreated/AVmock  100%; inhibition rate (%) = (1  AVtreated/
AVmock)  100%.
2.7. Cell cycle assay and apoptosis assay
Cell cycle and apoptosis were evaluated by ﬂow cytometry. The
cultured cells were digested in 0.25% trypsin for 1 min. After termi-
nation of the digestion by adding equal culture medium, the sam-
ples were centrifuged at 1500 rpm for 5 min, rinsed twice with
PBS, and then ﬁxed in 70% ethanol at 4 C overnight. After ﬁxation,
cells were washed twice at room temperature with 1 ml of wash
buffer (PBS + 0.1% BSA) following centrifugation at 10000 rpm for
1 min, and the pellets were resuspended in the wash buffer. In
300 ll PBS, approximately 3  105 cells were stained with 3 ll pro-
pidium iodide (PI) at 4 C for 30 min for cell cycle assay and with
3 ll annexin V-FITC at room temperature for 10 min for apoptosis
assay. The cells were then analyzed using MultiCycle software
(Becton Dickinson, San Jose, CA, USA) using the FACS Canto™ ﬂow
cytometer (Becton Dickinson).
2.8. Transwell migration assay
Cell migration was determined after gene transfection using a
transwell system. Approximately 6.0  104 cells were vaccinated
into the upper surface of the transwell membrane and cultured
at 37 C under a 5% CO2 atmosphere for 24 h, 48 h, and 72 h.
The number of cells that migrated to the lower surface of the
membrane was counted under a microscope (200
magniﬁcation).Fig. 1. Expression of eIF4E in cervical lesions. Immunohistochemical staining. (A) chron
200.2.9. Statistical analysis
Statistical software SPSS version 17.0 (SPSS, Inc., Chicago, IL,
USA) was used to perform the statistical analyses. The chi-squared
test, Spearman rank correlation, and one-way analysis of variance
(ANOVA) were used.
3. Results
3.1. Expression of eIF4E in different degrees of cervical tumors
To investigate the relationship between eIF4E and cervical le-
sions, eIF4E expression in the cervical lesions was tested. Cells po-
sitive (+) for eIF4E expression displayed yellow and brown
granules in the cytoplasm and nucleus, but cells negative () for
eIF4E expression showed no staining at all (Fig. 1). The positive
expression rates of eIF4E were 9.5% in chronic cervicitis, 40.0% in
CIN I, 61.3% in CIN II–III, and 90.5% in SCC, with signiﬁcant differ-
ences between any two groups except CIN I versus CIN II–III
(Table 1).
3.2. E6 mRNA expression was inhibited effectively by shE6s
The shRNA fragments targeting E6 (shE6s) were synthesized,
and shE6 vectors with green ﬂuorescent protein (GFP) were con-
structed. Sequence analysis showed that the fragments were in-
serted correctly in the plasmid. Then the recombinant plasmids
were transfected into Hela cells. Green ﬂuorescence was observed
at 12 h, 24 h, 36 h, and 48 h in Hela cells under a ﬂuorescence
microscope. GFP expression rates were 17.2% (24 h) and 41.6%
(48 h), as determined by ﬂow cytometric detection. Therefore,
the transfection was successful.
Forty-eight hours after the transfection, the E6 mRNA level in
the NC group was similar to that in the mock group, as detectedic cervicitis (); (B) CINI (+); (C) CINIII (+); (D) ICC (+). All images were magniﬁed
Table 1
Expression of eIF4E in cervical lesions.
Group Total eIF4E
Positive Positive rate (100%)
Cervicitis 21 2 9.5 a
CIN I 25 10 40 b
CIN II–III 31 19 61.3 c
ICC 21 19 90.5 d
Comparisons between a, b, c and d: v2 = 30.076, P < 0.001. a versus b: v 2 = 5.498,
P < 0.05; a versus c, v 2 = 13.935, P < 0.001. a versus d: v 2 = 27.524, P < 0.001. b
versus c: v 2 = 2.512, P > 0.05. b versus d: v 2 = 12.481, P < 0.001. c versus d: v 2
= 5.420, P < 0.05.
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detection, shE6-13 signiﬁcantly inhibited of E6. Among the trea-
ted groups, shE6-3 displayed the highest E6 inhibition rate,
approximately 81.0% (P < 0.001) compared with the NC group
(Fig. 2A). In the RT-PCR and agarose gel detection, two distinct
bands with expected sizes were observed for the E6 gene
(137 bp) and the gene (224 bp) in all groups (Fig. 2B). In the Image
J band analysis, E6 mRNA expression level in shE6-2 (P < 0.05) and
shE6-3 (P < 0.01) increased, compared with the NC group, but E6
mRNA expression levels in the shE6-1 groups signiﬁcantly de-
creased (Fig. 2B). Among the treated groups, shE6-3 displayed
the highest E6 inhibition rate, approximately 80.0%. The resultsFig. 2. Knockdown of E6 in Hela cells down-regulated eIF4E expression. E6 and eIF4E w
detected by real-time PCR. (B) Detection of E6 mRNA expression by RT-PCR. (C) eIF4E mR
Detection of eIF4E mRNA expression by RT-PCR. (E) eIF4E protein expression decre
immunocytochemistry. Mock, untreated Hela cells; NC, blank vector group; PBS, PBS wa
shE6-3 (24 h), eIF4E staining after 24 h of shE6-3 transfection; shE6-3 (48 h), eIF4E stainin
P < 0.01.were very similar between the real-time PCR and RT-PCR
detections.
3.3. E6 knockdown in Hela cells down-regulated eIF4E expression
After shE6 transfection for 48 h, the eIF4E mRNA level in the NC
group was similar to that in the mock group, according to the re-
sults of both real-time PCR and RT-PCR detection. In real-time
PCR detection, eIF4E mRNA levels in shE6-13 groups were signif-
icantly decreased compared with those in the NC group (P < 0.05).
Among the treated groups, shE6-3 showed the highest eIF4E inhi-
bition rate, approximately 76.0% (P < 0.001) (Fig. 2C). In the RT-PCR
and agarose gel detections, two distinct bands with expected sizes
were observed for the eIF4E gene (132 bp) and the GAPDH gene
(224 bp) (Fig. 2D). According to Image J band analysis, the eIF4E
mRNA level of the shE6-2 group increased compared with the NC
group (P < 0.05), the eIF4E mRNA level of the shE6-3 group also in-
creased (P < 0.01), but the eIF4E mRNA level in the shE6-1 group
signiﬁcantly decreased (Fig. 2D). Among the treated groups,
shE6-3 showed the highest eIF4E inhibition rate, approximately
70.0%. The results were similar between the real-time PCR and
RT-PCR detections. The change of eIF4E level corresponded to the
change of E6 level in the shE6-13 groups.
We used IHC to test eIF4E expression in Hela cells. eIF4E protein
was localized in cytoplasm and nucleus, which was stained brown
or brownish (Fig. 2E). In the untreated Hela group, the eIF4E posi-ere normalized with GAPDH. (A) E6 mRNA expression decreased by shE6s at 48 h
NA expression decreased after E6 knockdown at 48 h detected by real-time PCR. (D)
ased in Hela cells at 24 h and 48 h after the transfection of shE6, detected by
s used to replace eIF4E antibody; Untreated Hela, normal eIF4E level of Hela cells;
g after 48 h of shE6-3 transfection. : shE6s versus NC, P < 0.05; : shE6s versus NC,
Fig. 3. shE6-3 or sieIF4E trasfection negatively inﬂuenced Hela cell biology. (A) shE6-3 inhibited the proliferation of Hela cells detected by CCK-8 assay. (B) sieIF4E inhibited
the proliferation of Hela cells detected by CCK-8 assay. (C) shE6-3 inhibited the migration of Hela cells detected by transwell assay. Mock, untreated Hela cells; NC, blank
vector group; shE6-3, shE6-3 group. : shE6-3 versus NC, P < 0.01.
Table 2
Cell cycle change of Hela cells after shE6 transfection.
Group Percentage (x ± s, n = 3)
G1% S% G2%
Hela 33.536 ± 1.108 51.329 ± 1.656 15.165 ± 1.453
NC 37.186 ± 1.157 48.881 ± 1.604 13.967 ± 1.554
shE6-3 (24 h) 42.263 ± 1.754 43.974 ± 1.358 13.789 ± 1.603
shE6-3 (48 h) 51.252 ± 1.352* 36.647 ± 1.455* 12.095 ± 1.804
shE6-3 (72 h) 62.162 ± 1.853* 23.241 ± 1.652* 14.621 ± 1.506
* shE6 (48 h) versus NC, shE6 (72 h) versus NC, P < 0.01.
Table 3
Apoptosis change of Hela cells after shE6 transfection.
Group Percentage (x±s, n = 3)
V-FITC +/PI V-FITC +/PI+
Hela 0.780 ± 0.255 0.180 ± 0.168
NC 11.056 ± 1.256 5.818 ± 1.819
shE6-3 (24 h) 36.001 ± 2.201* 10.902 ± 1.403
shE6-3 (48 h) 40.901 ± 3.201* 10.702 ± 2.503
* shE6 (24 h) versus NC, shE6 (48 h) versus NC, P < 0.01.
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tion for 24 h and 48 h, the eIF4E positive rate of the cells was de-
creased to 90.49% and 44.05%, respectively. The staining intensity
became much weaker in the shE6-3 group than that in the un-
treated Hela group (Fig. 2E).
3.4. shE6 highly inhibited the proliferation and migration of Hela cells
and promoted cell apoptosis
Using a CCK-8 assay, the proliferation of Hela cells was detected
at 24 h, 48 h, and 72 h after shE6-3 transfection. The cell prolifera-
tion between the mock and NC groups was similar. Compared with
the NC group, cell proliferation was signiﬁcantly inhibited in the
shE6-3 group (P < 0.01) (Fig. 3A). The inhibition rates in the shE6
group were 10.2% (24 h), 21.6% (48 h), and 13.7% (72 h).
Cell cycle distribution was analyzed by ﬂow cytometry. The cell
cycle between the mock and NC groups was similar. Compared
with the NC group, the cell cycle in the shE6-3 group obviously
changed. The G0/G1 phase cell numbers signiﬁcantly increased
by 8.7% (24 h), 17.7% (48 h), and 28.6% (72 h). S phase cell numbers
signiﬁcantly decreased by 7.4% (24 h), 14.6% (48 h) and 28.1%
(72 h); G2/M phase cell numbers showed no signiﬁcant change
(Table 2). These outcomes indicate that shE6-3 inhibited the prolif-
eration of Hela cells by arresting cells at G0/G1 phase.
The annexin V-FITC/PI double-staining method was adopted for
detecting cell apoptosis. The amount of apoptosis between the
mock and NC groups was similar. Compared with the NC group,
the ratio of V-FITC+/PI cells (early apoptosis cells) in the shE6-3
group was signiﬁcantly increased by 25.0% (24 h) and 29.7%
(48 h), while the ratio of V-FITC+/PI+ cells (late apoptosis cells) in-
creased, but not signiﬁcantly (Table 3).
sieIF4E inhibited the proliferation of E6-positive Hela cells.
Using a CCK-8 assay, cell proliferation was detected at 24 h, 48 h,
and 72 h. Cell proliferation between the mock and NC groups
was similar. Compared with the NC group, cell proliferation in
the sieIF4E group was obviously inhibited (P < 0.01) (Fig. 3B). Theinhibition rates were 7.6% (24 h), 27.5% (48 h), and 32.1% (72 h).
The inhibition rate in the sieIF4E group was close to that in the
shE6-3 group at 24 h and 48 h, and at 72 h this rate became higher
than that in the shE6-3 group.
To analyze the migration of Hela cells after shE6 transfection, a
transwell migration assay was performed. The migrating cell num-
bers were similar between the mock and NC groups. Compared
with the NC group, the migrating cells in the shE6-3 group de-
creased to 40.92 ± 8.785 (24 h), 72.79 ± 10.337 (48 h), and
148.44 ± 16.696 (72 h) (P < 0.01) (Fig. 3C).
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migration of HPV-negative C33A cells
E6 and mutant E6 expression vectors and the NC vectors were
respectively transfected into HPV-negative C33A cells. The mRNAs
of E6, mutant E6, and GAPDH were detected by RT-PCR. Three
bands with expected sizes for E6 gene (271 bp), mutant E6 gene
(256 bp) and GAPDH gene (224 bp) were observed. The E6 band
and mutant E6 band were observed in the E6 and mutant E6
groups (E6m) (Fig. 4A, left), respectively. According to the Image
J analysis, the mRNA level in the E6 group was similar to the mRNAFig. 4. E6 induced eIF4E expression and promoted the proliferation and migration of C3
pEGFP blank plasmid group; E6m, E6 mutant group; E6, E6 expression vector group. E6 a
expression vector was transfected into C33A cells, detected by RT-PCR. (B) eIF4E expressio
PCR. (C) Transfection of the E6 gene promoted the proliferation of C33A cells, detected by
as detected by a transwell migration assay. : E6/E6m versus NC, P < 0.05; : E6/E6m vlevel in the E6m group. No expression of either E6 or mutant E6
was detected in the mock and NC groups (Fig. 4A, right).
RT-PCR was performed to detect eIF4E mRNA after the transfec-
tion of E6 or mutant E6 expression vectors for 20 h. Two bands
with expected sizes for the eIF4E gene (132 bp) and the GAPDH
gene (224 bp) were seen in all groups. The eIF4E bands were much
stronger in the E6 and the E6m groups than in the mock group or
the NC group (Fig. 4B, left). According to Image J analysis, the eIF4E
mRNA level was similar between the mock and NC groups. Com-
pared with the NC group, eIF4E mRNA increased by 54.3% in the
E6m group and by 58.1% in the E6 group (P < 0.01) (Fig. 4B, right).3A cells. Cells were divided into four groups: Mock, untreated C33A cell group; NC,
nd eIF4E were normalized with GAPDH in RT-PCR. (A) E6 expression at 20 h after E6
n at 20 h after E6 expression vector was transfected into C33A cells, detected by RT-
CCK-8 assay. (D) Transfection of the E6 gene promoted the migration of C33A cells,
ersus NC, P < 0.01.
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that the mutant E6 functioned similarly.
The proliferation of C33A cells after gene transfection is shown
in Fig. 4C. By comparison with the NC group, the proliferation rates
increased by 29.96% (24 h), 25.07% (48 h), and 39.87% (72 h) in the
E6m group (P < 0.05) and by 46.10% (24 h), 67.31% (48 h), and
90.51% (72 h) in the E6 group (P < 0.01). According to cell migration
detection, the numbers of migrating cells in the mock and NC
groups were similar at each time point. Compared with the NC
group, the migrating cells in the E6 group increased to
487.93 ± 29.687 (24 h), 703.63 ± 42.786 (48 h), and
901.77 ± 60.21 (72 h). The migrating cells in the E6 m group in-
creased to 416.66 ± 31.074 (24 h), 699.71 ± 45.869 (48 h), and
877.03 ± 57.926 (72 h) (P < 0.01) (Fig. 4D).
4. Discussion
The results of this study show that the over-expression of eIF4E is
associatedwith themalignancy of cervical lesions. Physiologically, a
small amount of eIF4E is expressed and contributes to the mainte-
nance of normal cell functions such as the growth, differentiation
and apoptosis. Recently, researchers have recognized that the
over-expression of eIF4E is usually associated with cancer [2,3].
Studies have shown that the over-expression of eIF4E increases
abnormal translation of a series of malignant transformation–re-
lated proteins. The molecules then promote cell survival, prolifera-
tion, resistance to apoptosis, out of control of malignant
transformation, invasion, metastasis, and angiogenesis [14]. In this
study, we detected eIF4E expression levels of chronic cervicitis,
CIN I, CIN II–III, andcervical squamous cell carcinoma.We found that
the positive expression rates of eIF4E increased following themalig-
nant progression of cervical lesions. These results are consistent
with the eIF4E RNA levels of Van Tranppen [5] and the eIF4E protein
levels of Lee [6]. Our study has further conﬁrmed that the over-
expression of eIF4E is closely related to the occurrence and develop-
ment of CC. These results indicate the potential of eIF4E as an impor-
tant molecular marker for the diagnosis and therapy of CC.
We conclude that E6 induces eIF4E expression in CC based on
the following evidence: (1) down-regulation of E6 decreased eIF4E
mRNA and protein levels in HPV-positive Hela cells; (2) the degree
of eIF4E down-regulation was correlated with the degree of E6 si-
lence in the transfection experiments with shE6-1, shE6-2, and
shE6-3 in Hela cells; and (3) gene transfection with E6 expression
plasmids induced eIF4E transcriptional expression in C33A cells
(HPV, eIF4E+). To the best of our knowledge, we are the ﬁrst to
determine conclusively that E6 induces the transcription of eIF4E.
This could be one of the mechanisms of the over-expression of
eIF4E in CC.
However, whether E6 induces eIF4E transcription directly or
indirectly remains unknown. The evidence indicates that E6 might
activate eIF4E transcription partly through the P53 gene, the ﬁrst
E6-targeted protein to be discovered. Binding and degradation of
p53 are the speciﬁc functions of the E6 protein. E6 can recruit
E6AP ubiquitin enzymes and bind them to the p53 core area,
resulting in the degradation of P53 in HPV-positive cells [15,16].
Secondly, P53 inhibits the transcription of eIF4E by indirectly
inhibiting the promoter activity of eIF4E [17]. Studies have found
that p53 inhibits eIF4E gene transcription and protein translation.
P53 is able to bind c-Myc and remove it from eIF4E promoter re-
gion where c-Myc binds and enhances eIF4E transcription [18].
Thus, it is reasonable to infer that E6 induces eIF4E transcription
through the P53 pathway. From another perspective, although
most of the activities of E6 have been found to be mediated by pro-
tein–protein interactions, studies have reported that the HPV E6
proteins could bind speciﬁcally to four-way DNA junctions [19].We cannot ignore the probability that E6 directly up-regulates
eIF4E by binding DNA. Our future studies will aim to conﬁrm this
hypothesis.
Interestingly, although to a lesser degree, in this study the mu-
tant E6 induced the transcription of eIF4E and increased the prolif-
eration of the cells, as did E6. Compared with the E6 gene, the
mutant E6 exhibited a decreased ability to target p53 for degrada-
tion [20,21]. Therefore, the residual p53 after E6m-induced degra-
dation might partly affect eIF4E expression and cell proliferation.
Indeed, E6 initiated and promoted the carcinogenesis of CC,
probably through eIF4E. We found that E6 transfection into HPV-
negative C33A cells increased eIF4E expression, accelerated cell
proliferation, and reduced apoptosis. Knocking down E6 or eIF4E
in HPV-positive Hela cells caused similar degrees of reduction of
cell proliferation and apoptosis resistance. Inhibition of eIF4E
expression in Hela cells with high E6 expression caused inhibition
of proliferation and cell cycle arrest. These results, taken together,
indicate that eIF4E is one of the key players in HPV carcinogenesis.
Furthermore, it is well known that HPV E6 and E7 share a pro-
moter and produce a bicistronic transcript. Therefore, knockdown
of E6 or E7 might affect each gene. In this study, we ﬁrst knocked
down E6 in HPV-positive Hela cells and observed the down-regu-
lation of eIF4E and corresponding changes of cell biology. Consid-
ering the interactions between E6 and E7, these results may have
been caused by a single E6 or by E6/E7. Subsequently, the HPV-
negative C33A cells without both E6 and E7 genes were chosen
to investigate the effect of a single E6 gene on eIF4E. We transfec-
ted C33A cells with an E6 expression vector. As a result, the expres-
sion of E6 signiﬁcantly up-regulated eIF4E in the absence of E7,
indicating that E6 induced eIF4E. In addition, the degree of E6-in-
duced eIF4E transcription was similar to the degree of inhibition
of eIF4E in the E6 knockdown experiment. This phenomenon indi-
cates that the down-regulation of eIF4E in the ﬁrst experiment was
caused mainly by the knockdown of E6 but not of E7. Thus, we con-
clude that E6 does induce eIF4E in CC cells.
In conclusion, this study has conﬁrmed eIF4E over-expression in
cervical tumors, and we have further determined that the mecha-
nism of eIF4E over-expression is subject to E6 induction. Over-ex-
pressed eIF4E inﬂuences CC occurrence and development in many
aspects, including cell proliferation, cell cycle progression, migra-
tion, and apoptosis. Therefore, eIF4E emerges as a key player in
the carcinogenesis of HPV-induced cancer and is a potential target
for CC therapy.
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